ALK and neoplasm: To address this unmet need, our proposed strategy—generating patient‐matched variant ALK fusion models (both in vitro and in vivo), systematically investigating their oncogenic mechanisms, biological functions, and tumor‐driving molecular pathways, and identifying effective therapeutic interventions—could help standardize and optimize treatment paradigms for patients with tumors driven by variant ALK fusions.